California Track-and-Trace Law Is Good Model, EMD Serono Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has been tracking shipments of its growth hormone agent Serostim since 2002 to forestall counterfeiting and fraudulent claims and backed a full track-and-trace system during a forum sponsored by Pew Health Group. But while the system makes good business sense for a specialty firm, the acknowledgement could complicate the existing political picture for industry.
You may also be interested in...
PDUFA Negotiations: REMS Mud-Slinging, Supply Chain Compromising, GAIN Diminishing?
PhRMA and GPhA exchange unpleasantries over the legislative pay-for; FDA offers a compromise track-and-trace program that would use the industry proposal as a starting point; structure of antibiotic incentives still unresolved.
Track And Trace System Could Start With RxTEC As Foundation, FDA Says
Compromise proposal from agency would allow lot-level tracking at first, if there was a “clear path” to a more advanced system in subsequent years.
User Fee Conference Cmte. Could Be Relatively Messy After Clean Floor Votes
House and Senate avoided some contentious issues when passing their user fee bills, leaving them to an informal conference committee to work out, ideally before the end of June.